# GLP-1s and Antipsychotic Weight Gain: A Trial Cut Short

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/glp1-and-antipsychotic-weight-gain

> Semaglutide produced 13.88% weight loss against 0.42% on placebo in people taking clozapine, without altering clozapine levels or psychotic symptoms. The trial ended at 31 of an intended 80 because the drug ran out.

## Key points

- 13.88% weight loss vs 0.42% on placebo at 36 weeks, from just 31 participants.
- No change in clozapine or norclozapine levels, and no change in PANSS scores.
- Recruitment stopped in June 2024 because the investigational product was unavailable.
- A strong signal, not a settled answer. The authors call for larger confirmatory trials.

People with schizophrenia die 16 to 20 years earlier than the general population, mostly from cardiometabolic disease. Clozapine, the most effective antipsychotic there is for treatment-resistant illness, is associated with weight gain and metabolic dysfunction.[1] That is one of the sharpest trade-offs in medicine. A 2025 trial tested whether semaglutide could ease it, and got a striking answer from a very small number of people. A second Danish trial has since asked the same question at more than twice the size and in a broader group; it is covered in [antipsychotics and metabolic harm](https://glpwatchdog.org/research/antipsychotics-and-metabolic-harm).

## What COaST found

COaST was an Australian randomized, placebo-controlled, blinded trial, run independently of pharmaceutical industry support, with its methods informed by people with lived experience. Adults aged 18 to 64 with schizophrenia or schizoaffective disorder, on clozapine for at least 18 weeks and with a BMI of 26 or more, were assigned to weekly semaglutide titrated to 2.0 mg or to placebo for 36 weeks.[1]

At 36 weeks the semaglutide group had lost **13.88%** of body weight against **0.42%** on placebo, a between-group difference of 13.46 percentage points (p below 0.0001).[1]

> **That result came from 31 people.** Fifteen on semaglutide, sixteen on placebo. A difference that large with a p-value that small is notable, but a trial this size cannot establish how well it generalizes. The authors say so themselves, calling the findings encouraging and pointing to the need for larger confirmatory trials. Read it as a strong signal, not as a settled answer.

## Why it ended at 31

The trial intended to recruit 80 participants. Recruitment began in August 2022 and was suspended in June 2024, not because of a safety problem or a lack of interest, but because the investigational product was unavailable.[1]

> The shortage that emptied pharmacy shelves also stopped a trial in one of the most under-served populations in medicine, at 31 of an intended 80.

This register spends most of its time on the commercial side of GLP-1 supply: who is selling what, at what price, and whether it is what it claims to be. This is the same shortage, arriving somewhere else. When demand for a weight-loss drug outruns manufacturing, the research that would tell clinicians how to use it safely in the people who need it most is competing for the same vials.

## The findings that mattered most were not about weight

For anyone taking clozapine, two questions come before weight loss, and COaST measured both.

- **Clozapine levels did not change.** There were no differences in clozapine or norclozapine concentrations between the groups.[1] Clozapine has a narrow therapeutic window and a serious monitoring burden, so a drug that shifted its levels would be a real problem.
- **Psychotic symptoms did not change.** No differences appeared in PANSS scores.[1] The worry that metabolic treatment might destabilize psychiatric illness was not borne out here.
- **Tolerability was unremarkable.** No serious adverse events were judged related to treatment, and rates of constipation were low.[1]

The wider literature points the same way on the safety question. A 2024 systematic review and meta-analysis of GLP-1 drugs in antipsychotic-induced weight gain (which could only pool exenatide and liraglutide, since nothing newer had enough data) found that neither adversely affected psychopathology.[2]

## What the older drugs achieved

That same meta-analysis is a useful calibration, because it shows how much the newer drugs changed the picture. Across five randomized trials and one cohort study, liraglutide produced a mean weight loss of 4.70 kg and [exenatide](https://glpwatchdog.org/research/exenatide-byetta-bydureon-weight-loss) 2.48 kg, and the exenatide result did not reach statistical significance.[2] Other drugs that add weight, such as [gabapentin and pregabalin](https://glpwatchdog.org/research/gabapentin-and-pregabalin-weight-gain), have no comparable GLP-1 trial at all.

Against that, a 13.88% body-weight reduction is a different order of result. It is also from a much smaller sample, on a newer drug, and the comparison is across separate trials rather than a head-to-head. Our [note on reading evidence across trials](https://glpwatchdog.org/research/the-peptide-menu-what-has-human-trials) covers why that distinction matters.

> **Nothing here is an argument against clozapine.** It remains the most effective antipsychotic for treatment-resistant schizophrenia, and its metabolic cost is a reason to manage that cost rather than to abandon the drug that works. Any change to psychiatric medication belongs with the prescribing psychiatrist, and this is a conversation to have with them rather than a decision to make from a web page.

## Frequently asked questions

### Can semaglutide help with antipsychotic weight gain?

A 2025 randomized trial in people on clozapine found 13.88% body weight reduction at 36 weeks against 0.42% on placebo. It is a strong signal from a very small trial (31 participants), and the authors call for larger confirmatory studies.

### Does it interfere with clozapine?

In that trial, no. There were no differences in clozapine or norclozapine concentrations between the semaglutide and placebo groups, which matters because clozapine has a narrow therapeutic window.

### Could it destabilize psychiatric symptoms?

It did not in this trial: PANSS scores showed no differences between groups. A separate 2024 meta-analysis of exenatide and liraglutide in antipsychotic-induced weight gain also found no adverse effect on psychopathology.

### Why was the trial so small?

It was designed for 80 participants but recruitment was suspended in June 2024 because the investigational product was unavailable. The supply shortage that affected pharmacies also curtailed this trial, which finished with 31 people.

### Should someone stop their antipsychotic to avoid the weight gain?

That is not what this evidence supports and it is not a decision to make outside psychiatric care. Clozapine remains the most effective antipsychotic for treatment-resistant schizophrenia; the metabolic cost is something to manage with the prescribing psychiatrist.

## References

1. Siskind D, Baker A, Arnautovska U, et al. Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator-blinded, randomised controlled trial in Australia. The Lancet Psychiatry. 2025. PMID: 40506208. https://pubmed.ncbi.nlm.nih.gov/40506208/
2. Bak M, Campforts B, Domen P, et al. Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica. 2024. PMID: 39048532. https://pubmed.ncbi.nlm.nih.gov/39048532/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1s and Antipsychotic Weight Gain: A Trial Cut Short", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/glp1-and-antipsychotic-weight-gain

Canonical HTML page: https://glpwatchdog.org/research/glp1-and-antipsychotic-weight-gain

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
